ClinicalTrials.gg
Status unknownNCT04809142Updated Mar 22, 2021

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

A Phase 3 interventional study of TQB2450 Injection and Anlotinib hydrochloride in Advanced Biliary Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced biliary cancer.

02

Conditions studied

  • Advanced Biliary Cancer
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. or cytologically confirmed biliary adenocarcinoma, including intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC) and gallbladder cancer (GBC).

2.18 years and older, (ECOG) performance status of 0 to 1; ≥ 3 months;Weight ≥40 kg or ≥18.5.

  1. At least one (based on 1.1). 4. Previous gemcitabine or fluorouracil-based combination chemotherapy failed.

5.Adequate laboratory indicators. 6. No pregnant or breastfeeding women, and a negative pregnancy test. 7. Understood and Signed an form.

Exclusion criteria

Exclusion Criteria:

    1. Tumor disease and medical history:

      1. Has central nervous system (CNS) and/or cancerous meningitis or ;
      2. Has other malignant tumors within 5 years;
      3. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear;
      4. Severe bone damage caused by tumor bone metastasis;
      5. Has uncontrolled and repeated drainage pleural effusion, pericardial effusion, and ascites;
      6. Partial or complete intestinal obstruction and complete biliary obstruction that cannot be relieved; 2. Previous anti-tumor therapy:

      <!-- -->

      1. Has received Anlotinib Hydrochloride Capsules, Bevacizumab Injection, and such as PD-1, PD-L1, and CTLA-4 in prior treatment;
      2. Have received anti-tumor therapy within 4 weeks before the first administration;
      3. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy; 3.Comorbidities and medical history:

      <!-- -->

      1. Active or C;
      2. Kidney abnormalities;
      3. Abnormal thyroid function;
      4. Cardiovascular abnormalities;
      5. Gastrointestinal abnormalities;
      6. History of immunodeficiency;
      7. Has risk of bleeding;
      8. Uncontrollable active bacterial, fungal or viral infections;
      9. Lung diseases, such as interstitial pneumonia, obstructive lung disease, and history of symptomatic bronchospasm;
      10. Allergies to the ingredients of the study drug;
      11. Have a history of neurological or psychiatric disorders
      12. According to the researcher's point of view, other severe, acute or chronic medical or mental illnesses or laboratory abnormalities that may increase the risks associated with participating in the study, or may interfere with the interpretation of the study results;
      13. Have a history of pituitary or adrenal dysfunction
      14. Has received major surgical treatment, open , or obvious traumatic injury within 28 days before the first administration;
      15. Long-term unhealed wound or fracture;
      16. Has drug abuse history that unable to abstain from or mental disorders; 4. Has participated in other clinical trials within 30 days before the study. 5. Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first administration.

        1. Pregnant or breastfeeding women. 7. According to the judgement of the investigators, there are other factors that may lead to the termination of the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
392 participants (estimated)

Study arms

  • Experimental
    TQB2450+Anlotinib

    TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

    Drug: TQB2450 Injection · Drug: Anlotinib hydrochloride

  • Active comparator
    Chemotherapy

    Capecitabine tablets combined with oxaliplatin injection or gemcitabine hydrochloride injection. Each cycle is 3 weeks.

    Drug: Oxaliplatin injection · Drug: Capecitabine tablets · Drug: Gemcitabine hydrochloride injection

Interventions

  • TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.

  • Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

  • Oxaliplatin injection 130 mg/m2 administered IV on Day 1 of each week in 3-week cycles;

  • Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;

  • Gemcitabine hydrochloride injection administered 1000 mg/m2 IV on Day 1 and Day 8 of each week in 3-week cycles.

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 40 weeks

Secondary outcomes

  1. Progression free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: up to 24 weeks

  2. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 24 weeks

  3. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 24 weeks

  4. Duration of response(DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 24 weeks

  5. Progression-free survival at 6 months

    Percentage of participants whose PFS has achieved at least 6 months.

    Time frame: up to 6 months

  6. Overall survival at 6 months

    Percentage of participants whose OS has achieved at least 6 months.

    Time frame: up to 6 months

  7. Overall survival at 12 months

    Percentage of participants whose OS has achieved at least 12 months.

    Time frame: up to 12 months

07

Study locations

1 of 17 sites recruiting
  • Anhui Provincal Hospital
    Hefei, Anhui 230001, China
    Not yet recruiting
  • Beijing Chao-Yang Hospital,Capital Medical University
    Beijing, Beijing 100020, China
    Not yet recruiting
    • Guangyu An, Doctor · Contactagybjcyyy@163.com
    • Guangyu An, Doctor · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Not yet recruiting
    • Aiping Zhou, Doctor · Contactzhouap1825@126.com · 010-87788800
    • Aiping Zhou, Doctor · Principal investigator
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
    Not yet recruiting
  • Beijing Youan Hospital,Captical Medical University
    Beijing, Beijing 100069, China
    Not yet recruiting
    • Dondong Lin, Doctor · Contactldd1231@126.com
    • Dondong Lin, Doctor · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing 100089, China
    Recruiting
    • Lin Shen, Doctor · Contactdoctorshenlin@sina.cn · 010-88196340
    • Lin Shen, Doctor · Principal investigator
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing 102218, China
    Not yet recruiting
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Not yet recruiting
  • Affiliated Hospital of Hebei University
    Baoding, Hebei 071000, China
    Not yet recruiting
    • Aimin Zang, master · Contactbooszam@sina.com
    • Aimin Zang, master · Principal investigator
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061001, China
    Not yet recruiting
  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei 067000, China
    Not yet recruiting
    • Qingshan Li, bachelor · Contactlibing200865@126.com
    • Qingshan Li, bachelor · Principal investigator
  • Harbin Medical University Affiliated Tumor Hospital
    Harbin, Heilongjiang 150081, China
    Not yet recruiting
    • Yanqiao Zhang, Doctor · Contactyanqiaozhang@126.com
    • Yanqiao Zhang, Doctor · Principal investigator
  • Henan Tumor Hospital
    Zhengzhou, Henan 450003, China
    Not yet recruiting
    • Xiaobing Chen, Doctor · Contact2290773710@qq.com
    • Xiaobing Chen, Doctor · Principal investigator
  • Tongji Medical College of HUST
    Wuhan, Hubei 430040, China
    Not yet recruiting
    • Hong Qiu, Doctor · Contacttjqiuhong@163.com
    • Hong Qiu, Doctor · Principal investigator
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410000, China
    Not yet recruiting
    • Chuang Peng, Doctor · Contact1518364280@qq.com
    • Chuang Peng, Doctor · Principal investigator
  • The First Peoples Hospital of Changzhou
    Changzhou, Jiangsu 213000, China
    Not yet recruiting
    • Haijiao Yan, Doctor · Contacthaijiao8237@163.com
    • Haijiao Yan, Doctor · Principal investigator
  • The First Bethune Hospital of Jilin University
    Changchun, Jilin 130000, China
    Not yet recruiting
    • Wei Li, Doctor · Contactjdyylw@163.com
    • Wei Li, Doctor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Mar 2022, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 22, 2021
StartActual
Feb 4, 2021
Primary completionEst.
Mar 18, 2022
CompletionEst.
Feb 1, 2023
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04809142
Responsible party
Sponsor
First posted
Mar 22, 2021
Start date
Feb 4, 2021
Primary completion
Mar 18, 2022 (estimated)
Completion
Feb 1, 2023 (estimated)
Last update
Mar 22, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Benmelstobart · Catequentinib hydrochloride

Start the discussion